Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792626 | 0.87 | TSHR (0.48) | KMT2AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL206197 | 0.85 | TSHR (0.57) | KMT2AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL11002006 | 0.85 | LMNA (0.47) | KMT2ANPC1RAB9AALDH1A1LMNA | |
| SCHEMBL19213270 | 0.85 | CES2 (0.52) | KMT2ANPC1RAB9AALDH1A1LMNA | |
| Ethyl Acetate SCHEMBL9406126 | 0.85 | KMT2A (0.42) | KMT2AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL6573663 | 0.84 | KMT2A (0.57) | KMT2AKDM4EALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL10824597 | 0.84 | TSHR (0.55) | KMT2AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL31441001 | 0.84 | ALDH1A1 (0.45) | KMT2ANPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4833152 | 0.84 | ALDH1A1 (0.45) | KMT2ANPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8887009 | 0.82 | KMT2A (0.44) | KMT2ANPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119593106-A | Production process of antistatic nylon fiber | 福建鑫森合纤科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119593106-A | Production process of antistatic nylon fiber | 福建鑫森合纤科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-105189456-B | Covalent inhibitors of KRAS G12C | 亚瑞克西斯制药公司 | 2017-12-19 | — | — | CN | disclosed |
| CN-105189456-A | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC | 2015-12-23 | — | — | CN | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| CN-102584919-B | 4''-O-carbamate clarithromycin derivative with electron withdrawing group substituted terminal, preparation method for intermediate of derivative and application of derivative | UNIV SHANDONG | 2014-12-10 | — | — | CN | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101967146-A | Ep4 receptor inhibitors to treat rheumatoid arthritis | PRIZER JAPAN INC | 2011-02-09 | — | — | CN | disclosed |
| CN-100579518-C | Use of EP4 receptor ligands for the manufacture of a medicament for the treatment of IL-6 related disorders | PFIZER | 2010-01-13 | — | — | CN | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| CN-1319092-A | Benzamide derivatives and their use as cytokine inhibitors | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | CN | disclosed |
| US-3932409-A | CYTOSTATIC AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | KMT2A 2917/4885KDM4E 3701/4885NPC1 312/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | KMT2A 4355/4885KDM4E 3970/4885NPC1 1338/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | KMT2A 3764/4885KDM4E 1206/4885NPC1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.